---
schema_version: "secwatch.filing_event.v1"
accession: "0001522767-25-000167"
form_type: "8-K"
ticker: "MRMD"
cik: "0001522767"
company_name: "MARIMED INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:19:59.911574+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MariMed Q2 revenue $39.6M, adjusted EBITDA $4.9M; net loss narrows YoY

## Summary
- Revenue of $39.6M for Q2 2025, down 2% YoY from $40.4M; GAAP net loss improved to $1.3M from $1.6M.
- Non-GAAP adjusted EBITDA of $4.9M (12% margin), up from $4.4M (11% margin) in Q2 2024; company was cash flow positive.
- CEO cites 'Expand the Brand' strategy; growth in Massachusetts, full-quarter Delaware contributions, and entry into Pennsylvania.
- Six-month net loss widened to $6.7M from $2.9M, while non-GAAP net loss also widened; adjusted EBITDA margin fell to 10%.
- Company anticipates catalysts in H2: adult-use Delaware, new Maine license, Pennsylvania entry, and M&A optionality.

## SEC filing metadata
- accession: 0001522767-25-000167
- form_type: 8-K
- ticker: MRMD
- cik: 0001522767
- company_name: MARIMED INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/0001522767-25-000167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/mrmd-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001522767-25-000167
- JSON: https://secwatch.observer/filing/0001522767-25-000167.json
- Plain text: https://secwatch.observer/filing/0001522767-25-000167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.